| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6364 |
Provisional Schedule
| Committee meeting: 1 | 03 October 2024 |
| Expected publication | 11 December 2024 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
| External Assessment Group | Southampton Health Technology Assessment Centre (SHTAC), University of Southampton |
Stakeholders
| Companies sponsors | Amgen (tarlatamab) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Roy Castle Lung Cancer Foundation |
| Professional groups | Association of Cancer Physicians |
| British Thoracic Oncology Group | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | Novartis (topotecan) |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 March 2024 | Invitation to participate |
| 22 January 2024 - 05 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6364 |
| 22 January 2024 | In progress. Scoping commenced. |
| 22 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual